|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Urinary Incontinence: Major Milestones |
|
|
|
|
€ 4 000,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mars 2005 |
Taille du document : |
42 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 10 pages | Octobre 2005 | Anglais
|
|
|
| Main
focus: |
urinary incontinence,pharmaceutical,...
|
| Research
focus: |
market definition,strategy,market segmentation |
| Geographic
focus: |
usa,united kingdom,hong kong,spain,china,canada,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
3 500,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities
334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process.
Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth
173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph |
795,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century
189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
Pfizer's Recent Takeover
15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001
128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass.
The Pharmaceu |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Urinary Incontinence: Major Milestones |
|
|
Introduction
Urinary incontinence has three main subtypes including stress, urge and mixed, and is estimated to affect 100 million women in the seven major markets. Drug therapy for urinary incontinence has focused on overactive bladder, worth over $1.3 billion in 2003. Lilly/BI's Yentreve, launched in 2004, is the first drug treatment for stress incontinence, the most prevalent subtype of the condition.
Scope
In-depth primary research interviews with key opinion leaders from the US and Europe to add insight on market developments and unmet needs
Analysis of recent market events including new drug launches and impact on the market
Secondary resources include IMS MIDAS sales and promotional data across the seven major markets, IDdb, IMS R&D Focus, Medline
Highlights
Despite the high prevalence of urinary incontinence among women, few are diagnosed and treated due to a number of barriers preventing help-seeking behavior. There is a need to greater disease education among patients to lessen embarrassment about the condition and raise awareness of effective treatments.
The UI market was worth $1.3 billion in 2003 with sales dominated by leading overactive bladder drugs including Detrol (Pfizer) and oxybutynin in its various forms. New drug launches in OAB Vesicare (Yamanouchi) and Enablex (Novartis) could usurp Pfizer's dominance, while Yentreve will open up a new and underserved segment and driving growth.
Opinion leaders have identified a number of unmet needs in the urinary incontinence market, particularly the need for greater support for health professionals in terms of differentiating, diagnosing and treating UI subtypes in the long term and the need for greater disease awareness both among patients and physicians.
Reasons to Purchase
Understand barriers to treatment in the female UI population including obstacles in help-seeking behavior and difficulties in the diagnostic pathway
Identify physicians key concerns in urinary incontinence including unmet needs and desirable attributes of novel drugs for Overactive Bladder
Evaluate new drugs entering the market including key efficacy and safety trial data and their potential impact on the market
|
|
|
PPLSEN
|
|
|
|
|
